Medicago strives to improve world health by delivering world-class products and services to the global life sciences industry – while paying special attention to customer requirements and sustainability. We invite biotech, medtech and pharma companies to advance their positions by partnering with us for their research, diagnostics or production.

Medicago Inc. was a Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as bioreactors to produce proteins, candidate vaccines, and medications.

Medicago is a top provider of products targeting the life science industry – including biological buffers, lectins, bioactive molecules, reagents and immunological kits. With a broad and dynamic product range we have grown to become a trusted partner to many of the world’s leading life science companies since our foundation in 1995.

2023年2月3日 · Mitsubishi Chemical Group is shutting down Medicago Inc., a COVID-19 vaccine manufacturer with headquarters in Quebec City. A year ago, Medicago's plant-based COVID-19 vaccine, Covifenz, was...

Medicago is a genus of flowering plants, commonly known as medick or burclover, in the legume family (Fabaceae). It contains at least 87 species and is distributed mainly around the Mediterranean Basin, [2][3] and extending across temperate Eurasia and sub-Saharan Africa. [1] .

2023年5月22日 · Medicago has been a pioneer and a leader in the commercial development of plant molecular farming, particularly vaccine production by transient expression in Nicotiana benthamiana...

2023年2月3日 · Late this week, Medicago’s last remaining shareholder, Mitsubishi Chemical Group, said it would “cease all its operations” at Medicago proper, as well as the biotech’s R&D branch and its U ...

2022年3月1日 · Canada has approved Medicago's plant-based COVID-19 vaccine. The new shot itself is an impressive development, but the technology it's built on suggests that we may be growing more drugs in greenhouses in the coming years. Just under two years ago, Canadian biotech firm Medicago began developing a plant-based COVID-19 vaccine.

2019年，Medicago完成了基于植物的VLP（HA）疫苗的第二阶段临床研究。 这些VLP疫苗候选物产生了细胞和体液免疫反应，导致产生了针对四种不同流感毒株（两种流感A型和两种流感B型）的抗体，以及交叉保护。

2023年2月6日 · Medicago公司位于加拿大魁北克，是一家成立于1997年的疫苗和抗体药物研发商，公司的主力产品是植物源性新冠疫苗Covifenz。Medicago公司的疫苗技术路线与传统的疫苗开发路线有着显著的差异化，Medicago公司在利用植物叶子提取类病毒颗粒（VLPs）开...